Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. News
Mar 11, 2024 - businesswire.com
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Jan 10, 2024 - businesswire.com
HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP
Harpoon Therapeutics, Inc. Quantitative Score
About Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Harpoon Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Harpoon Therapeutics, Inc. Financials
Table Compare
Compare HARP metrics with: | |||
|---|---|---|---|
Earnings & Growth | HARP | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | HARP | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | HARP | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | HARP | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Harpoon Therapeutics, Inc. Income
Harpoon Therapeutics, Inc. Balance Sheet
Harpoon Therapeutics, Inc. Cash Flow
Harpoon Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Neutral |
| Debt/Equity Ratio | Strong Buy |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Harpoon Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Ms. Julie M. Eastland M.B.A. | Pres, Chief Executive Officer, Sec. & Director |
| Dr. Natalie R. Sacks M.D. | Consultant |
| Ms. Georgia L. Erbez | Consultant |
| Dr. Luke N. Walker M.D. | Chief Medical Officer |
| Ms. Wendy Chang | Senior Vice President of HR |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Julie M. Eastland M.B.A. | Pres, Chief Executive Officer, Sec. & Director | Female | 1964 | 910.77K |
| Dr. Natalie R. Sacks M.D. | Consultant | 1965 | 751.79K | |
| Ms. Georgia L. Erbez | Consultant | Female | 1967 | 484.9K |
| Dr. Luke N. Walker M.D. | Chief Medical Officer | 1972 | 424.43K | |
| Ms. Wendy Chang | Senior Vice President of HR | Female | -- |
Harpoon Therapeutics, Inc. Insider Trades
| Date | 11 Mar |
| Name | New Leaf Biopharma Opportunities II, L.P. |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 395783 |
| Date | 11 Mar |
| Name | New Leaf Biopharma Opportunities II, L.P. |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 10000 |
| Date | 11 Mar |
| Name | New Leaf Biopharma Opportunities II, L.P. |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 299430 |
| Date | 11 Mar |
| Name | New Leaf Biopharma Opportunities II, L.P. |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 85750 |
| Date | 11 Mar |
| Name | SILVERNAIL LAUREN P |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 5000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 11 Mar | New Leaf Biopharma Opportunities II, L.P. | Director, 10 percent owner | Disposed | D-Return | 395783 |
| 11 Mar | New Leaf Biopharma Opportunities II, L.P. | Director, 10 percent owner | Disposed | D-Return | 10000 |
| 11 Mar | New Leaf Biopharma Opportunities II, L.P. | Director, 10 percent owner | Disposed | D-Return | 299430 |
| 11 Mar | New Leaf Biopharma Opportunities II, L.P. | Director, 10 percent owner | Disposed | D-Return | 85750 |
| 11 Mar | SILVERNAIL LAUREN P | Director | Disposed | D-Return | 5000 |